Reactivity of a humanized antibody (hPankoMab) towards a tumor-related MUC1 epitope (TA-MUC1) with various human carcinomas.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Fan XN;Fan XN; Karsten U; Goletz S; Cao Y
  • Source:
    Pathology, research and practice [Pathol Res Pract] 2010 Aug 15; Vol. 206 (8), pp. 585-9. Date of Electronic Publication: 2010 Apr 18.
  • Publication Type:
    Journal Article; Research Support, Non-U.S. Gov't
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Gustav Fischer Verlag Country of Publication: Germany NLM ID: 7806109 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1618-0631 (Electronic) Linking ISSN: 03440338 NLM ISO Abbreviation: Pathol Res Pract Subsets: MEDLINE
    • Publication Information:
      Publication: Stuttgart : Gustav Fischer Verlag
      Original Publication: Stuttgart, New York, Fischer.
    • Subject Terms:
      Antibodies, Monoclonal* ; Antibody Specificity*; Antigens, Neoplasm/*immunology ; Carcinoma/*diagnosis ; Mucin-1/*immunology; Humans ; Immunohistochemistry
    • Abstract:
      Humanized antibodies against tumor-related antigens are now established reagents for in vivo diagnostics and for therapeutic approaches, and are increasingly developed. Humanized PankoMab (hPankoMab), a humanized form of PankoMab directed against a novel tumor-related MUC1 epitope (TA-MUC1), was recently developed for clinical application. In the present study, the reactivity of hPankoMab with various human cancers was systematically studied by immunohistochemistry on 137 surgical specimens, including lung, breast, gastric, colorectal, liver, cervical, kidney, thyroid, and other carcinomas, as well as on several non-epithelial malignancies. The study was performed on paraffin sections without antigen retrieval. hPankoMab reacted strongly with carcinomas originating from glandular or squamous epithelia, weakly with hepatocellular carcinomas, and not with sarcomas. The binding sites of hPankoMab in carcinomas were found around the whole cell surface and, in most cases, also in the cytoplasm of cancer cells.
    • Accession Number:
      0 (Antibodies, Monoclonal)
      0 (Antigens, Neoplasm)
      0 (MUC1 protein, human)
      0 (Mucin-1)
    • Publication Date:
      Date Created: 20100420 Date Completed: 20101006 Latest Revision: 20151119
    • Publication Date:
      20231215
    • Accession Number:
      10.1016/j.prp.2010.03.006
    • Accession Number:
      20400237